Table 1.
Patients characteristics and postoperative complications.
| No Complication | Infective complications | P (No complications group vs Infective complications group) | No infective complications | P (No complication group vs No infective complications group) | |
|---|---|---|---|---|---|
| Characteristic | N = 58 | N = 53 | N = 16 | ||
| Sex (n, %) | |||||
| Male | 16 (27,6%) | 19 (35,8%) | 0,4 | 4 (25%) | 1 |
| Female | 42 (72,4%) | 34 (64,2%) | 0,4 | 12 (75%) | 1 |
| Age (years) (mean-ranges) | 61,4 (37-74) | 59,5 (29-77) | 0,3 | 61,5 (36-75) | 0,9 |
| BMI (kg/m2) (mean +- SD) | 24,7 (3,9) | 25,3 (+-4,9) | 0,5 | 26,1 (+-8,4) | 0,4 |
| ASA Score | |||||
| ASA 1-2 | 32 (55,2%) | 32 (60,3(%) | 0,7 | 7 (43,7%) | 0,4 |
| ASA 3-4 | 26 (44,8%) | 21 (39,7%) | 0,7 | 9 (56,3%) | 0,4 |
| Origin of PM (n, %) | |||||
| Colorectal | 21 (36,2%) | 31 (58,5%) | 0,02 | 6 (37,5%) | 1 |
| Ovarian | 23 (39,7%) | 13 (24,5%) | 0,1 | 6 (37,5%) | 1 |
| Peritoneum | 12 (20,7%) | 6 (11,3%) | 0,2 | 4 (25%) | 0,7 |
| Neoadjuvant chemotherapy (n, %) | 49 (71%) | 48 (90,6%) | 0,4 | 10 (62,5%) | 0,08 |
| PCI (mean, +- SD) | 7 (+- 6.3) | 8,9 (+-6.5) | 0,1 | 9,1 (+- 6.1) | 0,4 |
| HIPEC (n, %) | |||||
| Oxaliplatine | 35 (60,3%) | 36 (67,9%) | 0,7 | 10 (62,5%) | 0,9 |
| Mitomycine | 16 (27,6%) | 12 (22,6%) | 0,7 | 5 (31,2%) | 0,8 |
| Cisplatine | 7 (12,1%) | 4 (7,6%) | 0,5 | 1 (6,3%) | 0,7 |
| CC score (n, %) | |||||
| CC0 | 51 (87,9%) | 41 (77,4%) | 0,2 | 11 (68,8%) | 0.1 |
| CC1 | 4 (6,9%) | 9 (16,9%) | 0,1 | 3 (18,7%) | 0,2 |
| CC2 | 3 (5,2%) | 3 (5,7%) | 1 | 2 (12,5%) | 0,3 |
| Operative procedure (n, %) | |||||
| Resection and digestive anastomosis | 19 (32,8%) | 26 (49,1%) | 0,08 | 11 (68,7%) | 0.01 |
| Digestive resection without anastomosis | 9 (15,5%) | 13 (24,5%) | 0,2 | 1 (6,2%) | 0,7 |
| Gallbladder resection | 47 (81%) | 43 (73,6%) | 1 | 9 (56,3%) | 0,05 |
| Omentectomy | 47 (81%) | 43 (73,6%) | 1 | 11 (68,8%) | 0,3 |
| Liver resection or radiofrequency | 5 (8,6%) | 9 (17%) | 0,25 | 1 (6,3%) | 1 |
| Diaphragm resection | 1 (1,7%) | 1 (1,9%) | 1 | 0 (0%) | 0,4 |
| Total Peritonectomy | 12 (20,7%) | 6 (11,3%) | 0,2 | 4 (25%) | 0,7 |
| Ovariectomy | 15 (25,9) | 18 (34%) | 0,4 | 5 (31,3%) | 0,7 |
| Vaginal resection | 2 (3,5%) | 1 (1,9%) | 0,6 | 1 (6,3%) | 0,5 |
| Hysterectomy | 8 (13,8%) | 6 (11,3%) | 0,7 | 3 (18,8%) | 0,7 |
| Appendectomy | 16 (27,6%) | 7 (13,2%) | 0,1 | 2 (12,5%) | 0,4 |
| Splenectomy | 3 (5,2%) | 0 (0%) | 0,1 | 2 (12,5%) | 0,3 |
| Bladder resection | 1 (1,7%) | 1 (1,9%) | 1 | 0 (0%) | 0,4 |
|
Estimated blood loss (ml)
(mean +- SD) |
525 (+- 450) | 478 (+- 301) | 0.3 | 285 (+- 177) | 0.3 |
ASA Score, American Society of Anesthesiologists; BMI, body mass index; CC score, completeness of Cytoreduction score; HIPEC, hyperthermic intraperitoneal chemotherapy; n, number; PCI, peritoneal cancer index; PM, peritoneal metastasis; SD, standard deviation.
Bold values = p values < 0.05.